Using Science to Drive Social Change

Preeclampsia Awareness Month - May 2024

Awareness month at IBPL

May is Preeclampsia Awareness Month and 22 May every year is marked as World Preeclampsia Day.

We at Intignus Biotech Pvt. Ltd, are dedicating this month to raise awareness about this life-threatening condition.

Our slogan for 2024 is ‘Using Science to Drive Social Change’

Preeclampsia Introduction and disease burden

A pregnancy related diseases characterised by high blood pressure and the presence of protein in urine, Preeclampsia can be fatal to both the mother and the baby

This condition develops in 2% to 8% of all pregnant women and remains a major cause of maternal and perinatal morbidity and mortality worldwide. It is estimated that approximately 4 million women are diagnosed with PE each year, resulting in >70,000 deaths in women and 500,000 babies. Currently, the rate of this disease in developing countries is seven times higher than that in developed countries.

Need for a Screening Test
Early diagnosis and timely intervention can lead to a healthier pregnancy
of pregnancy related complications
2- %
maternal deaths yearly worldwide
+
fetal deaths worldwide
+ 0
annual rise in preeclampsia globally
0 %
Click to Download

Preeclampsia Infographics

Subscribe and follow us on social media

Preeclampsia Awareness Survey 2024

Did you know that every 7 minutes a woman dies of complications due to Preeclampsia?

22 May every year is marked as World Preeclampsia Day. As part of our commitment to Revolutionize women’s health, we are conducting a survey on Preeclampsia awareness.

Learn more about this grave condition and join us in raising awareness about it b taking the survey by clicking on the link or using the QR code.

The survey will remain open till 5 PM on 31st May 2024! 

 

Check out the surprising results from last year’s survey below!

Hear from the Experts

Sharing their Journey

PE survivor testimonials

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
John Doe
Designer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
John Doe
Designer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
John Doe
Designer

Community Outreach

Healthcare workers connected
Hospitals/Clinic sessions
Lives reached
0
PEscreen

Need for a tool for early detection

The current method of diagnosis of PE involves monitoring blood pressure, urine tests for proteinuria, blood tests to assess liver and kidney function, fetal monitoring via ultrasound, and measuring levels of serum biomarkers. Until recently, pregnant women were diagnosed for PE only after they showed elevated blood pressure and protein in the urine. As PE can worsen quickly, potentially causing severe and immediate complications unless the labour is induced; there is an unmet clinical need for early and point of care diagnostic tests. Early diagnosis (before 20 weeks of gestation), with the help of effective screening tests, can help the clinicians to manage PE effectively